Form 4: Enanta Pharmaceuticals Chief Medical Officer Reports Stock Transactions
SEC Form 4 Filing
Scott T. Rottinghaus, Chief Medical Officer of Enanta Pharmaceuticals, reports acquisition of shares through performance share units and disposition of shares to cover withholding taxes.
Summary
- On February 12, 2025, Scott T. Rottinghaus, the Chief Medical Officer of Enanta Pharmaceuticals, acquired 9,750 shares of common stock through the vesting of performance share units (PSUs).
- These PSUs vested based on the achievement of two-year research and development milestones in the 2023-2024 period, as determined by Enanta's Compensation Committee.
- Simultaneously, Rottinghaus disposed of 2,861 shares to cover withholding taxes due upon the settlement of the PSU awards at a price of $5.59 per share.
- Following these transactions, Rottinghaus beneficially owns 24,807 shares of Enanta Pharmaceuticals common stock.
Sentiment
Score: 6
Explanation: The sentiment is neutral. The filing reflects routine transactions related to executive compensation and tax obligations. The vesting of PSUs suggests achievement of R&D milestones, which is mildly positive.
Positives
- The vesting of performance share units indicates the achievement of research and development milestones, which can be seen as a positive sign for the company's progress.
Industry Context
Form 4 filings are standard disclosures required by the SEC to provide transparency into the transactions of company insiders, allowing investors to track ownership changes and potential alignment of interests.
Stakeholder Impact
- The transactions provide transparency to shareholders regarding executive compensation and ownership.
Key Dates
| Date | Description |
|---|---|
| 2023-2024 | Two-year period for research and development milestones related to PSU vesting. |
| 02/12/2025 | Date of stock acquisition and disposition. |
| 02/14/2025 | Date of signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.